Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 13;15(7):1543.
doi: 10.3390/v15071543.

Hyperimmune Globulins for the Management of Infectious Diseases

Affiliations
Review

Hyperimmune Globulins for the Management of Infectious Diseases

Ilaria Pati et al. Viruses. .

Abstract

This review is focused on the use of hyperimmune globulin therapy to treat some infectious diseases of viral or bacterial origin. Despite the introduction of antibiotics and vaccines, plasma immunoglobulin therapy from whole blood donation can still play a key role. These treatments provide passive transfer of high-titer antibodies that either reduces the risk or the severity of the infection and offer immediate but short-term protection against specific diseases. Antibody preparations derived from immunized human donors are commonly used for the prophylaxis and treatment of rabies, hepatitis A and B viruses, varicella-zoster virus, and pneumonia caused by respiratory syncytial virus, Clostridium tetani, Clostridium botulinum. The use of hyperimmune globulin therapy is a promising challenge, especially for the treatment of emerging viral infections for which there are no specific therapies or licensed vaccines.

Keywords: convalescent plasma; human immunoglobulin; hyperimmune globulins; infectious diseases; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Casadevall A., Scharff M.D. Return to the past: The case for antibody-based therapies in infectious diseases. Clin. Infect. Dis. 1995;21:150–161. doi: 10.1093/clinids/21.1.150. - DOI - PMC - PubMed
    1. Casadevall A. Passive antibody therapies: Progress and continuing challenges. Clin. Immunol. 1999;93:5–15. doi: 10.1006/clim.1999.4768. - DOI - PubMed
    1. Keller M.A., Stiehm E.R. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 2000;13:602–614. doi: 10.1128/CMR.13.4.602. - DOI - PMC - PubMed
    1. Stiehm E.R. Appropriate therapeutic use of immunoglobulin. Transfus. Med. Rev. 1996;10:203–221. doi: 10.1016/S0887-7963(96)80060-5. - DOI - PubMed
    1. Hsu J.L., Safdar N. Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases. Infect. Dis. Clin. North Am. 2011;25:773–788. doi: 10.1016/j.idc.2011.07.005. - DOI - PubMed